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Abstract
Basic calcium phosphate (BCP) crystals, including
hydroxyapatite, octacalcium phosphate (OCP) and carbonate-
apatite, have been associated with severe osteoarthritis and
several degenerative arthropathies. Most studies have
considered the chondrocyte to be a bystander in the
pathogenesis of calcium crystal deposition disease, assuming
that synovial cell cytokines were the only triggers of chondrocyte
activation. In the present study we identified direct activation of
articular chondrocytes by OCP crystals, which are the BCP
crystals with the greatest potential for inducing inflammation.
OCP crystals induced nitric oxide (NO) production and
inducible nitric oxide synthase (NOS) mRNA expression by
isolated articular chondrocytes and cartilage fragments, in a
dose-dependent manner and with variations over time. OCP
crystals also induced IL-1β  mRNA expression. Using
pharmacological and cytokine inhibitors, we observed that OCP
crystals induced NO production and inducible NOS mRNA
activation were regulated at both the transcriptional and the
translational levels; were independent from IL-1β  gene
activation; and involved p38 and c-Jun amino-terminal kinase
(JNK) mitogen-activated protein kinase (MAPK) pathways, as
further confirmed by OCP crystal-induced p38 and JNK MAPK
phosphorylation. Taken together, our data suggest that the
transcriptional inducible NOS response to OCP crystals
involved both the p38 and the JNK MAPK pathways, probably
under the control of activator protein-1. NO, a major mediator of
cartilage degradation, can be directly produced by BCP crystals
in chondrocytes. Together with synovial activation, this direct
mechanism may be important in the pathogenesis of destructive
arthropathies triggered by microcrystals.
Introduction
Crystals of calcium pyrophosphate dihydrate (CPPD) and
basic calcium phosphate (BCP), including octacalcium phos-
phate (OCP), carbonate-substituted apatite and tricalcium
phosphate, are the calcium-containing crystals most com-
monly associated with articular and periarticular disorders.
BCP crystals can cause acute attacks of inflammatory arthritis
[1] or acute calcific periarthritis [2], and in a few patients they
result in erosive arthritis [3]. More often, they are associated
with an exaggerated form of osteoarthritis (OA) or with joint
destruction [4-7]. The prevalence of CPPD and BCP microc-
rystals in patients with joint disease increases significantly with
ageing. These microcrystals have been identified in 60% of
joint fluids from patients with knee OA undergoing total arthro-
plasty [7,8]. More specifically, the presence of BCP crystals
correlates strongly with radiographic evidence of cartilaginous
degeneration [7,8]. Physical interactions between chondro-
cytes and BCP crystals could occur in vivo in various settings.
BCP crystals can be released from subchondral bone through
cartilage lesions. Interestingly, hypertrophic chondrocytes,
which are present in the superficial zone of osteoarthritic
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cartilage, can produce calcifying apoptotic bodies, resulting in
BCP formation in the perichondrocytic milieu [9].
The mechanism of cartilage degradation in BCP crystal-asso-
ciated OA remains unclear. Hypotheses include synovial lining
cell stimulation by BCP crystals, resulting in synovial cell pro-
liferation [10-12], release of matrix-degrading molecules [13-
20], and secretion of inflammatory mediators [21] and
cytokines that, in turn, stimulate chondrocytes to generate
matrix-degrading molecules [12,13,16,22,23].
Most studies have considered chondrocytes as passive
bystanders in the pathogenesis of BCP crystal associated OA
and CPPD disease. However, in primary OA chondrocytes
appear to play a major role in cartilage damage. In immunohis-
tochemistry studies chondrocytes expressed larger amounts
of inflammatory mediators and cytokines, such as IL-1β  and
tumour necrosis factor (TNF)-α  than did OA synoviocytes
[24], suggesting an active role for chondrocytes in cartilage
destruction.  In vitro, BCP crystals induced prostaglandin
secretion [13], collagenase [12] and metalloproteinase
(MMP)-13 mRNA accumulation, and MMP-13 protein secre-
tion by articular chondrocytes [16].
Osteoarthritic lesions may result from an imbalance between
anabolic and catabolic processes. Nitric oxide (NO) is a pleio-
tropic mediator that is intimately involved in the OA catabolic
process [25-28]. NO is synthesized via L-arginine oxidation by
a family of nitric oxide synthases (NOSs). Of the three known
NOS isomers, two are constitutively expressed (neural
ncNOS or NOS-1 and endothelium ecNOS or NOS-3) and
one is inducible (iNOS or NOS-2). Expression of iNOS has
been demonstrated in various cell types. Within the joint,
chondrocytes may be the main cell source of NO, and iNOS
expression is increased in human OA cartilage [29]. In animal
models of OA, treatment with the specific iNOS inhibitor N-
iminoethyl-L-lysine significantly reduced the progression of
structural changes [30,31]. This structural effect was accom-
panied by reductions in MMP synthesis, IL-1β  and prostaglan-
din E2 production, and chondrocyte apoptosis [32].
BCP crystals are heterogeneous in terms of their ultrastruc-
ture and physicochemical composition, and previous studies
[33,34] have shown differences in their phlogistic properties.
We studied OCP crystals, which are the BCP crystals that
produced the greatest degrees of inflammation in earlier stud-
ies [33,34]. Although OCP is one of the BCP crystals found in
joints [35], its biological significance is unclear. It could be del-
eterious to cartilage at some stages, resulting in inflammatory
reaction, but it could be also a precursor to hydroxyapatite,
which is a BCP crystal found at greater concentration in joints
but with reduced inflammatory capability. We postulated a
direct effect of BCP crystals on chondrocyte activation.
To investigate this hypothesis, we looked for effects of OCP
crystals on NO production by bovine cartilage organ cultures
and isolated articular chondrocytes. We also examined
whether OCP crystals activated iNOS expression through the
protein kinase signal transduction pathway involving Erk1/2
(p42/44), p38, and c-Jun amino-terminal kinase (JNK)
mitogen-activated protein kinases (MAPKs). Finally, we inves-
tigated whether IL-1β  release triggered by OCP crystals acted
as a secondary messenger of OCP crystal induced iNOS
expression.
Materials and methods
Reagents
Foetal bovine serum (FBS) was obtained from Dominique Dut-
scher (Brumath, France). Dulbecco's modified Eagle's
medium (DMEM) with high glucose (4.5%), phosphate-buff-
ered saline, penicillin, streptomycin, fungizone, Taq polymer-
ase, M-MLV reverse transcriptase, dNTP set, primers and
TRIzol reagents were obtained from Invitrogen (Cergy-Ponto-
ise, France). The pharmacological MAPK inhibitors PD98059
and SB203580, and JNK II inhibitor were purchased from Cal-
biochem (San Diego, CA, USA). NG-nitro-L-arginine methyl
ester (L-NAME), cycloheximide, actinomycin D, pepstatin,
aprotinin, leupeptin, phenylmethyl sulfofluoride, poly-(2-
hydroxyethyl methacrylate; poly-HEMA) and bacterial colla-
genase type II were obtained from Sigma-Aldrich (St Quentin
Fallavier, France). IL-1β  and IL-1 receptor antagonist (IL-1ra)
were purchased from R&D systems Inc. (Abingdon, Oxford,
UK).
Antibodies
Phospho-specific JNK (Thr183/Tyr185) and p38 (Thr180/
Tyr182), and total JNK and p38 antibodies were purchased
from Cell Signaling Technology (Ozyme, St Quentin Yvelines,
France). Polyclonal horseradish peroxidase-conjugated goat
anti-rabbit IgG was obtained from Sigma-Aldrich.
Articular cartilage organ cultures
Carpal–metacarpal joints of calves (<3 years of age) were pro-
vided by a local French slaughterhouse. Cartilage disks (15–
25 mg) were aseptically dissected from articular cartilage
slices and washed three times in DMEM containing 100 µg/ml
streptomycin, 100 IU/ml penicillin, and 0.25 µg/ml fungizone.
Disks were transferred to 96-well, flat-bottomed plates (TPP;
ATGC biotechnologie, Marne la Vallée, France) containing
DMEM with high glucose supplemented with 10% heat-inac-
tivated FBS and antibiotics (hereafter referred to as 'complete
medium') and cultured at 37°C in a humidified atmosphere
supplemented with 5% carbon dioxide. The medium was
changed 72 hours later to 200 µl DMEM with 1% FBS, and
OCP crystals or recombinant human IL-1β  were added 24
hours later.Available online http://arthritis-research.com/content/7/5/R915
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Chondrocyte isolation and culture
Bovine chondrocytes were isolated from carpal–metacarpal
cartilage, as described by Kuettner and coworkers [36].
Briefly, articular cartilage was cut into small pieces, and
chondrocytes were released by collagenase digestion using
bacterial collagenase type II (0.2% in DMEM) for 20 hours at
37°C with gentle shaking. Chondrocytes were then collected
through a 100 µm nylon cell strainer (Cell strainer, Falcon,
VWR International, Fontenay sous Bois, France), washed, and
plated at high density (107cells/ml) in complete medium. At
subconfluence, cells were starved in DMEM with 1% FBS for
24 hours and then harvested and replated at 106 cells/ml in
96-well, round-bottomed (for nitrite production studies) or 24-
well (for MAPK or iNOS activation studies) plates coated with
10% poly-HEMA [37]. Poly-HEMA coating prevents cell adhe-
sion and preserves the articular cartilage phenotype for up to
several weeks [38].
Octacalcium phosphate crystal preparation
Sterile, pyrogen-free OCP crystals (homogeneity in size 1.5 ±
0.5  µm; Ca/[P+CO3] ratio 1.33) were synthesized, as
described previously [33,39], by suspending calcium hydro-
gen phosphate dihydrate (5 g) in 300 ml of an aqueous solu-
tion of diammonium hydrogen phosphate (5 g) at 37°C for 48
hours. OCP crystal size and morphology were determined
using a Phillips EM 300 transmission electron microscope
(Philips, Eindhoven, The Netherlands) and their nature by X-ray
diffraction (INEL CPS 120 diffractometer; Enraf Nonius SA,
Sevran, France) and infrared spectroscopy (Perkin-Elmer FTIR
1760 spectrometer; Courtaboeuf, France) before and after
sterilization. Sterilization was by exposure to 60Co γ -radiation
by the CisBio International Company (Laboratoire des Pro-
duits d'Irradiation at the Commissariat à l'Energie Atomique,
Saclay, France). OCP crystals were confirmed to be pyrogen-
free, as shown previously [33].
Determination of nitrite level
NO accumulation was measured by the Griess reaction. Con-
fluent articular chondrocytes were seeded at a concentration
of 106  cells/ml as described above. Chondrocytes were
treated with various pharmacological inhibitors for 60 min, and
then stimulated by various doses of OCP crystals or IL-1β . For
the indicated times in the cell cultures and 4 days later in the
cartilage organ culture, 50 µl cell-free supernatants from
chondrocyte or articular cartilage organ cultures were mixed
with 150 µl Griess reagent. The NO2
- concentrations were
immediately determined by measuring absorbance at 550 nm
in an enzyme-linked immunosorbent assay plate reader. NO
measurements are expressed as µmol/l in culture superna-
tants and as µmol/l per mg cartilage where appropriate.
Preparation of cytoplasmic extracts for mitogen-
activated protein kinase studies
Nonadherent chondrocytes were treated with various pharma-
cological inhibitors for 60 min then stimulated with OCP crys-
tals or IL-1β . For the indicated times, chondrocytes were
collected and placed in lysis buffer (20 mmol/l Tris.HCl [pH
7.5], 150 mmol/l NaCl, 1% Triton X-100, 1 mmol/l EDTA, 1
mmol/l EGTA, 1 mmol/l sodium orthovanadate, 2.5 mmol/l
sodium pyrophosphate, 1 mmol/l β -glycerophosphate, 1
mmol/l phenylmethyl sulfofluoride, 1 µg/ml pepstatin, aprotinin
and leupeptin). After sonication, the cells were incubated on
ice for 15 min and centrifuged at 14,000 rpm for 10 min at
4°C. The supernatants containing cell lysates were collected,
and the protein concentrations were measured using the
method of Bradford and coworkers [40].
Western blotting
The cytoplasmic extracts (15 and 30 µg of protein was loaded
for p38 and JNK western blotting, respectively) were diluted in
Laemmli buffer and boiled at 95°C for 5 min. Proteins were
separated by 8% SDS-PAGE and transferred onto PVDF
membranes by electroblotting. The membranes were blocked
for 2 hours at room temperature in 5% nonfat dry milk in Tris-
buffered saline-Tween (TBS-T) and then washed three times
with TBS-T. The membranes were incubated overnight at 4°C
with phospho-anti-MAPK (1:1000) antibodies in 3% BSA
TBS-T. After washing with TBS-T, blots were incubated with a
horseradish peroxidase conjugated anti-rabbit antibody. The
protein complexes were visualized by chemiluminescence
using the ECL Western blotting detection reagents (Amer-
sham Pharmacia Biotech Inc., Orsay, France). The membranes
were subsequently stripped and reprobed with anti-total
MAPK (1:1000 for total p38, and 1:500 for total JNK)
antibodies.
RNA isolation and RT-PCR
Nonadherent chondrocytes were treated for 60 min with phar-
macological inhibitors and then stimulated with OCP crystals
or IL-1β . After cell collection, total RNA was isolated using TRI-
zol reagent, in accordance with the manufacturer's instruc-
tions. Then, 2 µg of each sample was reverse transcribed at
37°C for 50 min using the M-MLV RT-PCR system. The result-
ing cDNA samples were amplified by PCR.
The PCR primers for bovine iNOS [41] were as follows: sense,
5'-TAG AGG AAC ATC TGG CCA GG-3', corresponding to
positions 682–701; and antisense, 5'-TGG CAG GGT CCC
CTC TGA TG-3', corresponding to positions 1034-053.
These amplified a 372-bp product. The primers for IL-1β  [37]
were as follows: sense, 5'-TAC CTG AAC CCA TCA ACG
AAA-3', corresponding to positions 517–533; and antisense,
5'-GAT GAA TGA AAG GAT GCC CTC-3', corresponding to
positions 799–783. These amplified a 275-bp product. The
collagen IIα 1 primers [42] were as follows: sense, 5'-GAT
CCG CAA CAT GGA GAC TGG CGA-3'; and antisense,
5'CAA GAA GCA GAC AGG CCC TAT GTC CAC-3'. These
generated a 527-bp product. For the housekeeping gene
GAPDH (glyceraldehyde-3-phosphate dehydrogenase), the
sense primer was 5'-ATC ACC ATC TTC CAG GAG CG-3',Arthritis Research & Therapy    Vol 7 No 5    Ea et al.
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corresponding to positions 245–264, and the antisense
primer was 5'-CCT GCT TCA CCA CCT TCT TG-3', corre-
sponding to positions 817-798, which amplified a 579-bp
product. The PCR products were analyzed by electrophoresis
on 2% agarose gel containing ethidium bromide.
Statistical analysis
Each experiment was conducted at least three times. Data are
presented as the mean ± standard deviation unless indicated
otherwise. For the statistical analysis, post hoc tests were
done when analysis of variance results were significant. P <
0.05 was considered statistically significant. Statistical analy-
ses were conducted using GraphPad software (San Diego,
CA, USA).
Results
Octacalcium phosphate crystals stimulate NO 
production by both articular cartilage fragments and 
isolated articular chondrocytes, and induce iNOS mRNA 
in isolated articular chondrocytes
To investigate the role of OCP crystals in cartilage destruction,
we isolated bovine articular cartilage fragments and chondro-
cytes. Isolated articular chondrocytes were cultured in poly-
HEMA-coated plates, which is a nonadherent culture condi-
tion previously shown to prevent chondrocyte de-differentia-
tion [38]. OCP crystals induced dose-dependent NO
production (Fig. 1a) by normal isolated articular chondrocytes
incubated with the crystals for 24 hours. Under these condi-
tions, we checked that the nonadherent cells consistently
expressed collagen II mRNA 48 hours after stimulation (Fig.
2a). Significant NO release was achieved with crystal concen-
trations as low as 0.1 mg/ml, which is a level known to occur
in human synovial fluids. Between 1 and 3 mg/ml, a plateau
was reached, with no cytotoxic effects as assessed by trypan
blue exclusion (data not shown). We therefore used 0.5 mg/
ml of OCP crystals in further experiments.
Time-dependent stimulation of NO production was observed,
with significant levels as early as 8 hours after stimulation and
a further increase until the 4-day time point, with no plateau
(Fig. 1b). L-NAME, a nonspecific iNOS inhibitor, reduced NO
production by OCP crystal- and IL-1 stimulated chondrocytes
(Figure 1b). With articular cartilage fragments, statistically sig-
nificant NO production induced by OCP crystals was found
only 4 days after stimulation (Fig. 1c), whereas NO production
was detected 24 hours after IL-1β  stimulation (data not
shown). As previously demonstrated [43], IL-1β  stimulated
NO production by both isolated chondrocytes and articular
cartilage organ culture, and increased iNOS mRNA expres-
sion (Fig. 1a–c). NO production was associated with time-
dependent induction of iNOS mRNA expression, which was
increased after 4 hours, reached a plateau between 8 and 24
hours, and decreased 48 hours after stimulation (Fig. 2a,b).
Octacalcium phosphate crystal-induced NO production 
was regulated at both transcriptional and translational 
levels
As shown in Fig. 2a, OCP crystals induced iNOS mRNA tran-
scription in articular chondrocytes, followed 4 hours later by
NO production. NO production and iNOS mRNA expression
were inhibited when chondrocytes were pre-incubated for 1
hour with the transcription inhibitor actinomycin D. This effect
was dose-dependent, being significant with an actinomycin D
concentration as low as 20 ng/ml (Fig. 3a,b). With 100 ng/ml
actinomycin D, no toxic effect was detected by trypan blue
exclusion. Levels of iNOS mRNA decreased after 24 hours of
stimulation, whereas NO production continued to increase for
4 days, suggesting post-transcriptional regulation. This was
confirmed when preincubation of chondrocytes with the trans-
lation inhibitor cycloheximide at a dose as low as 20 ng/ml
resulted in a significant decrease in OCP crystal induced NO
release (Fig. 3c). Thus, NO production induced by OCP crys-
tals was regulated at both transcriptional and post-transcrip-
tional levels, as observed with IL-1β  (data not shown).
Octacalcium phosphate crystals induced IL-1β  
expression, but octacalcium phosphate crystal induced 
iNOS mRNA and NO production were independent of IL-
1β
Previous experiments have shown that BCP crystals induced
the production of inflammatory cytokines, including IL-1α , IL-6,
TNF-α  and IL-8, by peripheral adherent monocytes (Prudhom-
meaux and coworkers, Champy and coworkers, unpublished
data) and TNF-α  by macrophages [44]. Here, we demon-
strated that OCP crystals induced IL-1β  mRNA expression
(Fig. 4a). When we pretreated chondrocytes with IL-1 recep-
tor antagonist for 1 hour before stimulation with either OCP
crystals or IL-1β , we found that IL-1 receptor antagonist com-
pletely inhibited IL-1β -induced iNOS mRNA expression and
NO production but had no influence on the effects of OCP
crystals (Fig. 4b,c). This suggested that iNOS gene expres-
sion induced by OCP crystals was not mediated by a para-
crine or autocrine mechanism involving the IL-1β  receptor.
p38 and JNK MAPKs are activated by octacalcium 
phosphate crystals and are involved in octacalcium 
phosphate crystal induced iNOS expression and NO 
production
Because most studies support a role for MAPK pathways in
the regulation of iNOS expression, we used pharmacological
inhibitors to investigate the potential role for these pathways in
OCP crystal-induced iNOS gene expression and NO produc-
tion. The p38 MAPK inhibitor SB 203580, at a concentration
as low as 1 µmol/l significantly reduced NO production (Fig.
5a) and completely inhibited iNOS mRNA induction by crys-
tals (Fig. 5d). JNK II inhibitor also reduced NO production, at
a concentration as low as 2 µmol/l (Fig. 5b). Conversely the
p42/44 MAPK inhibitor PD 98059 had no effect, even at a
high concentration (30 µmol/l, data not shown). Results wereAvailable online http://arthritis-research.com/content/7/5/R915
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similar with IL-1β  used as a positive control (Fig. 5c). These
findings support involvement of both the p38 and the JNK
MAPK pathways in OCP crystal-induced NO production. We
then used immunoblotting to show that OCP crystals induced
p38 and JNK phosphorylation and that this effect was inhibited
by chondrocyte pretreatment with p38 or JNK MAPK inhibi-
tors, respectively (Fig. 6a,b).
Because BCP crystals activated c-Jun and c-Fos [45], and the
transcriptional factor activator protein (AP)-1 has been impli-
cated in iNOS regulation, we investigated the role for AP-1 in
OCP crystal-induced NO production. NO production
decreased significantly when chondrocytes were preincu-
bated with curcumin, an AP-1 inhibitor directed toward het-
erodimerization of c-jun-c-fos, at a concentration as low as 1
µmol/l. This inhibition of NO production was dose dependent
(Fig. 7).
Discussion
OCP crystals, the most potent inflammation-inducing BCP
crystals [33,34], are found in joint fluids [35]. In our study,
OCP crystals induced iNOS gene expression by isolated artic-
ular chondrocytes and NO production by both isolated
chondrocytes and cartilage fragments. The expression of
iNOS mRNA increased 4 hours after BCP crystal stimulation,
peaked between 8 and 12 hours, and decreased after 24
Figure 1
OCP crystal-induced NO release by articular cartilage fragments and isolated articular chondrocytes OCP crystal-induced NO release by articular cartilage fragments and isolated articular chondrocytes. Nonadherent articular bovine chondrocytes 
(106 cells/ml) were stimulated with OCP crystals (see Materials and method). Articular cartilage fragments were dissected and cultured as 
described in the Materials and method section. NO accumulation was determined with the Griess reaction. (a) Dose–response NO production by 
chondrocytes was determined 24 hours after stimulation with different doses of OCP crystals or IL-1β . (b) Kinetics of NO release was determined 
after stimulation with OCP crystals (0.5 mg/ml), IL-1β  (10 ng/ml) alone or preincubated with L-NAME (2 mmol/l), a nonspecific iNOS inhibitor (n = 3 
different experiments). (c) NO released by articular cartilage disks, and reported to cartilage dry weight, were measured 4 days after OCP crystals or 
IL-1β  (10 ng/ml) stimulation (n = 3). *P < 0.001, OCP versus control, L-NAME/OCP). L-NAME, NG-nitro-L-arginine methyl ester; OCP, octacalcium 
phosphate; PBS, phosphate-buffered saline.Arthritis Research & Therapy    Vol 7 No 5    Ea et al.
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hours, in agreement with findings reported by Terkeltaub and
coworkers [37] and by Adler and colleagues [41] after
stimulation by monosodium urate (MSU) crystals and Salmo-
nella dublin, respectively. NO production was significant in
culture supernatants as early as hour 8 and increased through-
out the 4-day poststimulation period. Using a nonspecific
iNOS inhibitor, L-NAME, we observed that the inhibition of NO
production was less marked after IL-1 stimulation compared
with OCP crystals. This could result from the magnitude of the
effect achieved by each reagent.
Previous studies suggested that BCP crystals may directly
activate articular chondrocytes to produce MMP-13 [16], col-
lagenase [12] and other MMPs capable of degrading carti-
lage, as well as to release prostaglandin [13]. Although
chondrocytes can ingest BCP crystals [13], BCP-induced
MMP production does not require intracellular dissolution of
the crystals [46]. In fibroblasts 4 hours after stimulation by
BCP crystals, BCP crystal endocytosis was not yet complete
and solubilization of the crystals had not yet occurred [47]. In
addition, BCP crystal phagocytosis by chondrocytes has been
observed after 24 hours [13], suggesting that in the present
study OCP crystal-induced iNOS expression did not require
this process.
The direct effect of OCP crystals on cells may involve an inter-
action between OCP crystals and cell surface receptor-like
structures, such as integrins [37]. Proteins bind to BCP crys-
tals, including OCP, and to MSU crystal surfaces [34,48,49]
and can modulate cell function in vivo and in vitro. In addition,
fibronectin fragments induced p38 and JNK MAPK activation
via interactions with integrins [50]. Tan and coworkers [51]
reported regulation of iNOS expression by an integrin-linked
kinase, which was an ankyrin repeat containing a serine/threo-
nine protein kinase that interacted with the cytoplasmic
domain of β 1 integrin [51]. Furthermore, Liu and Lioté [37]
found that, within a few minutes, MSU crystals activated sev-
eral molecules linked to the focal adhesion kinase complex,
most notably Pyk-2, which appeared to be central to p38
MAPK activation and promoted iNOS gene expression, NO
production and MMP-3 translation.
NO regulates chondrocyte and cartilage functions and often
acts as an IL-1β  second messenger. Although in vitro NO had
either catabolic [52-57] or anabolic [58-61] effects, in vivo
studies clearly demonstrated that inhibition of NO production
by N-iminoethyl-L-lysine reduced the progression of structural
damage in rabbits with experimentally induced OA [30,32].
NO inhibition was associated with reductions in MMP synthe-
sis, IL-1β  and prostaglandin E2 production, and chondrocyte
apoptosis [32]. As it has been demonstrated that IL-1β -
induced MMP production is NO dependent [54], the mecha-
nism of BCP crystal induced MMP-13 production by chondro-
cytes remains unknown [16]. One possibility is a direct effect,
similar to the induction of MMP-1 production by fibroblasts
stimulated by BCP crystals [20]. Alternatively, NO mediation
may be involved, as shown for MSU crystal-induced MMP-3 in
chondrocytes [37].
Figure 2
Stimulation of NO production and induction of iNOS mRNA expression by OCP crystals Stimulation of NO production and induction of iNOS mRNA expression by OCP crystals. Nonadherent bovine articular chondrocytes were stimu-
lated with OCP crystals (0.5 mg/ml) or IL-1β  (10 ng/ml). (a) iNOS and collagen II transcripts were detected in cell pellets by RT-PCR (see Materials 
and method). (b) Absorbance ratio (iNOS/GAPDH) of the RT-PCR. The RT-PCR was representative of three independent experiments, while NO 
release (triplicate experiments) and the absorbance ratio were expressed as mean ± standard deviation from the same three experiments. *P < 0.05, 
**P < 0.01, OCP versus control. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; iNOS, inducible nitric oxide synthase; OCP, octacalcium 
phosphate.Available online http://arthritis-research.com/content/7/5/R915
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Although this is the first report on iNOS production by bovine
articular chondrocytes treated with BCP crystals, iNOS
expression has been consistently described in chondrocytes
treated with various inflammatory cytokines, including inter-
feron-γ , TNF-α  and IL-1β  [43,62,63]. IL-1β  seems to be the
key cytokine in the induction of cartilage catabolism and plays
a pivotal role in the cartilage destruction typical of OA [64]. In
our experiments using IL-1 receptor antagonist, we found that,
although OCP crystals induced IL-1β  mRNA, iNOS mRNA
expression induced by OCP crystals were in part independent
from IL-1β . In contrast, iNOS mRNA expression and NO pro-
duction induced by IL-1β  were inhibited by IL-1 receptor
antagonist. These results are in agreement with MSU crystal
induced iNOS expression, as observed by Liu and Lioté [37].
As described for MSU crystals, IL-1β  and OCP crystal
induced iNOS mRNA expression by chondrocytes required
the p38 and JNK MAPK pathways, whereas Erk1/2 MAPK
was not involved. NO production was partially inhibited by low
p38 inhibitor concentration whereas iNOS mRNA expression
was markedly decreased, reflecting differences between
iNOS protein production and activity and transcriptional regu-
lation. Furthermore, NO production was assessed after 24
hours of stimulation and iNOS mRNA expression at 8 hours. A
preferential role for p38 and JNK MAPK in iNOS activation
was observed by Mendes and coworkers using IL-1β  stimula-
tion [65]. However, depending on the stimulus and the cell
type, MAPK may play a positive, negative, or neutral role in reg-
ulating iNOS expression. For instance both the p38 and p42/
44 MAPK pathways have been reported to be involved in
iNOS induction by IL-1β -stimulated cardiomyocytes [66].
Conversely, in pulmonary vascular smooth muscle cells, p38
MAKP inhibited IL-1β -mediated iNOS expression [67]. Also,
BCP crystal induced MMP-1 activation in skin fibroblasts was
activated by p42/44 MAPK [20]. Two hypotheses may explain
the variations in the role of p38 MAPK on iNOS expression.
One is that p38 MAPK exists as several isoforms, each
expressed by specific cell types; under this hypothesis, the
p38 MAPK inhibitors used in previous work and in the present
study may not be sufficiently selective to inhibit one specific
Figure 3
OCP crystal-induced NO production is dependent on both transcription and translation OCP crystal-induced NO production is dependent on both transcription and translation. Bovine articular chondrocytes cultured on poly-HEMA-
coated plates were stimulated with OCP crystals or IL-1β  for 24 hours with or without pretreatment with (a,b) AcD, an inhibitor of transcription, or 
(c) CycH, an inhibitor of translation. AcD, actynomycin D; CycH, cycloheximide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NO, nitric 
oxide; OCP, octacalcium phosphate; poly-HEMA, poly-(2-hydroxyethyl methacrylate).Arthritis Research & Therapy    Vol 7 No 5    Ea et al.
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p38 MAPK isoform. In support of this possibility, Guan and
coworkers [68] demonstrated that p38α  MAPK isoform
activation was required for IL-1β -induced stimulation of iNOS
production by rat glomerular mesangial cells; thus, overexpres-
sion of the kinase inactive mutant form of p38α  MAPK inhib-
ited IL-1β -induced iNOS expression. The second hypothesis
is that regulation of iNOS promoter may be complex and spe-
cific for each cell type [69].
Structural analysis of the 5' flanking region of the iNOS gene
has identified multiple binding sites for the transcriptional fac-
tor AP-1 [70], a heterodimer that is composed of the protein
products of Fos and Jun. BCP crystals induce c-jun, c-fos and
AP-1 in human fibroblasts [20,46]. In this study JNK MAPK
was also activated by OCP crystals, and OCP crystal induced
NO production was inhibited by curcumin, a c-fos/c-jun het-
erodimerization inhibitor. These results suggest a role for AP-
1 in OCP crystal induced iNOS gene expression, as demon-
strated by Marks-Konczalik and coworkers [70] in A549 cells
(human alveolar type II lung carcinoma cell line) stimulated by
a mixture of cytokines containing interferon-γ , TNF-α  and IL-1β .
Inhibition of iNOS by actinomycin and cycloheximide may
reflect, at least in part, inhibition of AP-1 complex synthesis,
normally induced by BCP crystals.
Conclusion
In summary, this study showed that OCP crystals, a member
of the family of BCP crystals, caused inflammation by directly
activating chondrocytes to induce IL-1β  and iNOS gene
expression and NO production. OCP crystal induced iNOS
activation was IL-1β  independent, and involved the p38 and
JNK MAPK pathways, probably under AP-1 control. These
results demonstrated that chondrocytes may play a direct and
active role in cartilage destruction by specific microcrystals.
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Figure 4
OCP crystal-induced iNOS mRNA expression and NO release is not IL-1β  dependent OCP crystal-induced iNOS mRNA expression and NO release is not IL-1β  dependent. Nonadherent articular chondrocytes were stimulated with 
OCP crystals or IL-1β  for 24 hours with or without pretreatment with IL-1ra for 1 hour. (a,b) IL-1β  and iNOS transcripts were assessed by RT-PCR 
and (c) NO release was measured in the supernatants. The RT-PCR was representative of three experiments. GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase; IL-1ra, IL-1 receptor antagonist; iNOS, inducible nitric oxide synthase; NO, nitric oxide; OCP, octacalcium phosphate.Available online http://arthritis-research.com/content/7/5/R915
R923
Figure 5
p38 and JNK MAPK pathways regulate OCP crystal induced NO production and iNOS mRNA expression p38 and JNK MAPK pathways regulate OCP crystal induced NO production and iNOS mRNA expression. Nonadherent bovine articular chondro-
cytes were stimulated with OCP crystals or IL-1β  for 24 hours with or without pretreatment (1 hour) with (a,c) SB 203580 (a p38 MAPK inhibitor), 
(b,c) JNK II inhibitor or (d) PD 58059 (an Erk1/2 MAPK inhibitor). iNOS transcripts (panel d) were assessed 8 hours after stimulation by OCP crys-
tals or IL-1β  by RT-PCR. The RT-PCR was representative of three experiments. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; iNOS, induc-
ible nitric oxide synthase; JNK, c-Jun amino-terminal kinase; NO, nitric oxide; OCP, octacalcium phosphate.
Figure 6
OCP crystal induced p38 and JNK MAPK activation OCP crystal induced p38 and JNK MAPK activation. Nonadherent bovine articular chondrocytes were stimulated with OCP crystals for 20 min with 
or without pretreatment (1 hour) with SB 203580 or JNK II inhibitor. Fifteen (p38 MAPK) or 30 µg (JNK MAPK) protein of cell lysates were subjected 
to SDS-PAGE/Western blot analysis. The blots were probed with phosphospecific (a) p38 and (b) JNK MAPK antibodies. To ensure equal loading, 
the blot was stripped and reprobed with total p38 MAPK or JNK antibodies. JNK, c-Jun amino-terminal kinase; OCP, octacalcium phosphate.Arthritis Research & Therapy    Vol 7 No 5    Ea et al.
R924
Authors' contributions
HKE participated in study design, contributed to all experi-
ments, analyzed results, and prepared and wrote the manu-
script. BU contributed to PCR studies and chondrocyte
cultures. CR prepared and analyzed OCP crystals. FL contrib-
uted to study design, analyzed results, prepared, wrote the
manuscript and supervised the work.
Acknowledgements
We gratefully acknowledge Dr Saunier, DVM, Mr Croisier, veterinary 
technician, and technicians from the Montceau-Les-Mines slaughter-
house for their expert assistance in obtaining joints from Charolais cat-
tle. We thank the Société Française de Rhumatologie (SFR grant 2002–
2003), INSERM, Association Rhumatisme et Travail, and Association 
pour la Recherche en Pathologie Synoviale (ARPS) for providing finan-
cial support to this study.
Hang Korng Ea, MD, received PhD support from the association Rhu-
matisme et Travail, the ARPS, and the Société Française de Rhumatol-
ogie. Benjamin Uzan received PhD funding from the ARPS and the 
Association Rhumatisme et Travail.
References
1. Schumacher HR, Somlyo AP, Tse RL, Maurer K: Arthritis associ-
ated with apatite crystals. Ann Intern Med 1977, 87:411-416.
2. McCarty DJ, Gatter RA: Recurrent acute inflammation associ-
ated with focal apatite crystal deposition. Arthritis Rheum 1966,
9:804-819.
3. Schumacher HR, Miller JL, Ludivico C, Jessar RA: Erosive arthri-
tis associated with apatite crystal deposition. Arthritis Rheum
1981, 24:31-37.
4. McCarty DJ, Halverson PB, Carrera GF, Brewer BJ, Kozin F: 'Mil-
waukee shoulder' – association of microspheroids containing
hydroxyapatite crystals, active collagenase, and neutral pro-
tease with rotator cuff defects. I Clinical aspects.  Arthritis
Rheum 1981, 24:464-473.
5. Halverson PB, Cheung HS, McCarty DJ, Garancis JC, Mandel N:
'Milwaukee shoulder' – association of microspheroids con-
taining hydroxyapatite crystals, active collagenase, and neutral
protease with rotator cuff defects. II Synovial fluid studies.
Arthritis Rheum 1981, 24:474-483.
6. Garancis JC, Cheung HS, Halverson PB, McCarty DJ: 'Milwaukee
shoulder' – association of microspheroids containing
hydroxyapatite crystals, active collagenase, and neutral pro-
tease with rotator cuff defects. III Morphologic and bio-
mechemical studies of an excised synovium showing
chondromatosis. Arthritis Rheum 1981, 24:484-491.
7. Derfus BA, Kurian JB, Butler JF, Daft LJ, Carrera GF, Ryan LM,
Rosenthal AK: The high prevalence of pathologic calcium crys-
tals in pre-operatives knees. J Rheumatol 2002, 29:570-574.
8. Halverson PB, McCarty DJ: Patterns of radiographic abnormal-
ities associated with basic calcium phosphate and calcium
pyrophosphate dihydrate crystal deposition in the knee. Ann
Rheum Dis 1986, 45:603-605.
9. Rutsch F, Terkeltaub R: Deficiencies of physiologic calcification
inhibitors and low-grade inflammation in arterial calcification:
lessons for cartilage calcification.  Joint Bone Spine 2005,
72:110-118.
10. Cheung HS, Van Wyk JJ, Russell WE, McCarty DJ: Mitogenic
activity of hydroxyapatite: requirement for somatomedin C. J
Cell Physiol 1986, 128:143-148.
11. Mitchell PG, Pledger WJ, Cheung HS: Molecular mechanism of
basic calcium phosphate crystal-induced mitogenesis. Role of
protein kinase C. J Biol Chem 1989, 264:14071-14077.
12. Mitchell PG, Struve JA, McCarthy GM, Cheung HS: Basic cal-
cium phosphate crystals stimulate cell proliferation and colla-
genase message accumulation in cultured adult articular
chondrocytes. Arthritis Rheum 1992, 35:343-350.
13. Cheung HS, Halverson PB, McCarty DJ: Phagocytosis of
hydroxyapatite or calcium pyrophosphate dihydrate crystals
by rabbit articular chondrocytes stimulates release of colla-
genase, neutral protease, and prostaglandins E2 and F2 alpha.
Proc Soc Exp Biol Med 1983, 173:181-189.
14. McCarthy GM, Mitchell PG, Cheung HS: The mitogenic
response to stimulation with basic calcium phosphate crystals
is accompanied by induction and secretion of collagenase in
human fibroblasts. Arthritis Rheum 1991, 34:1021-1030.
15. McCarthy GM, Mitchell PG, Struve JA, Cheung HS: Basic cal-
cium phosphate crystals cause coordinate induction and
secretion of collagenase and stromelysin. J Cell Physiol 1992,
153:140-146.
16. McCarthy GM, Westfall PR, Masuda I, Christopherson PA, Che-
ung HS, Mitchell PG: Basic calcium phosphate crystals activate
human osteoarthritic synovial fibroblasts and induce matrix
metalloproteinase-13 (collagenase-3) in adult porcine articu-
lar chondrocytes. Ann Rheum Dis 2001, 60:399-406.
17. Bai G, Howell DS, Roos BA, Howard GA, Cheung HS: Basic cal-
cium phosphate crystals up-regulate metalloproteinases but
down-regulate tissue inhibitor of metalloproteinases-1 and -2
in human fibroblasts. Osteoarthritis cartilage 2001, 9:416-422.
18. Reuben PM, Wenger L, Cruz M, Cheung HS: Induction of matrix
metalloproteinase-8 in human fibroblasts by basic calcium
phosphate and calcium pyrophosphate dihydrate crystals:
effect of phosphocitrate. Connect Tissue Res 2001, 42:1-12.
19. Reuben PM, Brogley MA, Sun Y, Cheung HS: Molecular mecha-
nism of the induction of metalloproteinases 1 and 3 in human
fibroblasts by basic calcium phosphate crystals. Role of cal-
cium-dependent protein kinase Cα .  J Biol Chem 2002,
277:15190-15198.
20. Sun Y, Wenger L, Brinckerhoff CE, Misra RR, Cheung HS: Basic
calcium phosphate crystals induce matrix metalloproteinase-
1 through the Ras/Mitogen-activated protein kinase/c-fos/
AP-1/metalloproteinase-1 pathway. Involvement of transcrip-
tion factor binding sites AP-1 and PEA-3. J Biol Chem 2002,
277:1544-1552.
21. Dayer JM, Evequoz V, Zavadil-Grob C, Grynpas MD, Cheng PT,
Schnyder J, Trechsel U, Fleisch H: Effect of synthetic calcium
pyrophosphate and hydroxyapatite crystals on the interaction
of human blood mononuclear cells with chondrocytes, syno-
vial cells, and fibroblasts. Arthritis Rheum 1987, 30:1372-1381.
22. Cheung HS, McCarty DJ: Mechanism of connective tissue dam-
age by crystals containing calcium. Rheum Dis Clin North Am
1988, 14:365-376.
Figure 7
Role of AP-1 transcription factor in the induction of NO production by  OCP crystals Role of AP-1 transcription factor in the induction of NO production by 
OCP crystals. Nonadherent bovine articular chondrocytes were stimu-
lated with OCP crystals or IL-1β  for 24 hours with or without pretreat-
ment (1 hour) with various doses of curcumin, an AP-1 inhibitor. NO 
release was measured in the supernatants. AP = activator protein; NO 
= nitric oxide; OCP = octacalcium phosphate;Available online http://arthritis-research.com/content/7/5/R915
R925
23. Cheung HS: Calcium crystal effects on the cells of the joint:
implications for pathogenesis of disease. Curr Opin Rheumatol
2000, 12:223-227.
24. Melchiorri C, Meliconi R, Frizzeiero L, Sylvestri T, Pulsatelli L, Maz-
zetti I, Borzi RM, Uguccioni M, Facchini A: Enhanced and coordi-
nated in vivo expression of inflammatory cytokines and nitric
oxide synthase by chondrocytes from patients with
osteoarthritis. Arthritis Rheum 1998, 41:2165-2174.
25. Abramson SB, Attur M, Amin AR, Clancy R: Nitric oxide and
inflammatory mediators in the perpetuation of osteoarthritis.
Curr Rheumatol Rep 2001, 3:535-541.
26. Lotz M: The role of nitric oxide in articular cartilage damage.
Rheum Dis Clin North Am 1999, 25:269-281.
27. Clancy R, Rediske J, Koehne C, Stoyanovsky D, Amin A, Attur M,
Iyama K, Abramson SB: Activation of stress-activated protein
kinase in osteoarthritis cartilage: evidence of nitric oxide
dependence. Osteoarthritis Cartilage 2001, 9:294-299.
28. Nishida K, Doi T, Matsuo M, Ishiwari Y, Tsujigiwa H, Yoshida A,
Shibahara M, Inoue H: Involvement of nitric oxide in chondro-
cyte cell death in chondro-osteophyte formation. Osteoarthritis
Cartilage 2001, 9:232-237.
29. Amin AR, Di Cesare PE, Attur MG, Tzeng E, Billard TR, Stuchin SA,
Abramson SB: The expression and regulation of nitric oxide
synthase in human osteoarthritis-affected chondrocytes: evi-
dence for up regulated neuronal nitric oxide synthase. J Exp
Med 1995, 182:2097-102.
30. Pelletier JP, Jovanovic D, Fernandes JC, Manning P, Connor JR,
Currie MG, Di Battista JA, Martel-Pelletier J: Reduced progres-
sion of experimental osteoarthritis in vivo by selective inhibi-
tion of inducible nitric oxide synthase. Arthritis Rheum 1998,
41:1275-1286.
31. Pelletier JP, Jovanovic D, Fernandes JC, Manning P, Connor JR,
Currie MG, Martel-Pelletier J: Reduction in the structural
changes of experimental osteoarthritis by a nitric oxide
inhibitor. Osteoarthritis Cartilage 1999, 7:416-418.
32. Pelletier JP, Jovanovic D, Lascau-Coman V, Fernandes JC, Man-
ning PT, Connor JR, Currie MG, Martel-Pelletier J: Selective inhi-
bition of inducible nitric oxide synthase reduces progression
of experimental osteoarthritis in vivo: possible link with the
reduction in chondrocyte apoptosis and caspase 3 level. Arthri-
tis Rheum 2000, 43:1290-1299.
33. Prudhommeaux F, Schiltz C, Lioté F, Hina A, Champy R, Bucki B,
Ortiz-Bravo E, Meunier A, Rey C, Bardin T: Variation in the inflam-
matory properties of basic calcium phosphate crystals accord-
ing to crystal type. Arthritis Rheum 1996, 39:1319-1326.
34. Prudhommeaux F, Meunier A, Rey C, Bardin T: Inflammatory
potential of in vivo aged basic calcium phosphate crystals.
Bioceramics 1998, 11:387-390.
35. McCarty DJ, Lehr JR, Halverson PB: Crystal populations in
human synovial fluid. Identification of apatite, octacalcium
phosphate and tricalcium phosphale.  Arthritis Rheum 1983,
26:1220-1224.
36. Kuettner KE, Pauli BU, Gall G, Memoli VA, Schenk RK: Synthesis
of cartilage matrix by mammalian chondrocytes in vitro: isola-
tion, culture characteristics and morphology. J Cell Biol 1982,
93:743-750.
37. Liu R, Lioté F, Rose DM, Merz D, Terkeltaub R: Proline-rich tyro-
sine kinase 2 and Src kinase signaling transduce monoso-
dium urate crystal-induced nitric oxide production and matrix
metalloproteinase-3 expression in chondrocytes.  Arthritis
Rheum 2004, 50:247-258.
38. Reginato AM, Iozzo RV, Jimenez SA: Formation of nodular struc-
tures resembling mature articular cartilage in long-term pri-
mary cultures of human fetal epiphyseal chondrocytes on a
hydrogel substrate. Arthritis Rheum 1994, 37:1338-1349.
39. Rey C, Shimizu M, Collins B, Glimcher MJ: Resolution-enhanced
Fourrier transform infrared spectroscopy study of the environ-
ment of phosphate ions in the early deposits of a solid phase
of calcium phosphate in bone and enamel, and their evolution
with age. I: Investigations in the upsilon 4 PO4 domain. Calcif
Tissue Int 1990, 46:384-394.
40. Bradford MM: A rapid and sensitive method for the quantifica-
tion of microgram quantities of protein utilizing the principle of
protein-dye binding. Ann Biochem 1976, 7:248-254.
41. Adler H, Frech B, Thöny M, Pfister H, Peterhans E, Jungi TW:
Inducible nitric oxide synthase in cattle. Differrential cytokine
regulation of nitric oxide synthase in bovine and murine
macrophages. J Immunol 1995, 154:4710-4718.
42. Ronzière MC, Roche S, Gouttenoire J, Démarteau O, Herbage D,
Freyria AM: Ascorbate modulation of bovine chondrocyte
growth, matrix protein gene expression and synthesis in
three-dimensional collagen sponges.  Biomaterials 2003,
24:851-861.
43. Badger AM, Cook MN, Lark MW, Newman-Tarr TM, Swift BA, Nel-
son AH, Barone FC, Kumar S: SB 203580 inhibits p38 mitogen-
activated protein kinase, nitric oxide production, and inducible
nitric oxide synthase in bovine cartilage-derived chondrocytes.
J Immunol 1998, 161:467-473.
44. Alwan WH, Dieppe PA, Elson CJ, Bradfield JW: Hydroxyapatite
and urate crystal induced cytokine release by macrophages.
Ann Rheum Dis 1989, 48:476-482.
45. Cheung HS, Mitchell PG, Pledger WJ: Induction of expression of
c-fos and c-mye protooncogenes by basic calcium phosphate
crystal: effect of beta-interferon.  Cancer Res 1989,
49:134-138.
46. McCarthy GM, Cheung HS, Abel SB, Ryan LM: Basic calcium
phosphate crystal-induced collagenase production: role of
intracellular crystal dissolution. Osteoarthritis Cartilage 1998,
6:205-213.
47. Borkowf A, Cheung HS, McCarty DJ: Endocytosis is required for
the mitogenic effect of basic calcium phosphate crystals in
fibroblasts. Calcif Tissue Int 1987, 40:173-176.
48. Terkeltaub RA, Santoro DA, Mandel G, Mandel N: Serum and
plasma inhibit neutrophil stimulation by hydroxyapatite crys-
tals. Evidence that serum α 2-HS glycoprotein is a potent and
specific crystal-bound inhibitor.  Arthritis Rheum 1988,
31:1081-1089.
49. Ortiz-Bravo E, Sieck MS, Schumacher HR: Changes in the pro-
teins coating monosodium urate crystals during active and
subsiding inflammation. Immunogold studies of synovial fluid
from patients with gout and of fluid obtained using the rat sub-
cutaneous air pouch model.  Arthritis Rheum 1993,
36:1274-1285.
50. Forsyth CB, Pulai J, Loeser RF: Fibronectin fragments and
blocking antibodies to α 2β 1 and α 5β 1 integrins stimulate
mitogen-activated protein kinase signaling and increase colla-
genase 3 (matrix metalloproteinase 13) production by human
articular chondrocytes. Arthritis Rheum 2002, 46:2368-2376.
51. Tan C, Mui A, Dedhar S: Integrin-linked kinase regulates induc-
ible nitric oxide synthase and cyclooxygenase-2 expression in
an NF-κ B-dependent manner.  J Biol Chem 2002,
277:3109-3116.
52. Pelletier JP, Lascau-Coman V, Jovanovic D, Fernandes JC, Man-
ning PT, Connor JR, Currie MG, Martel-Pelletier J: Selective inhi-
bition of inducible nitric oxide synthase in experimental
osteoarthritis is associated with reduction in tissue level of
catabolic factors. J Rheumatol 1999, 26:2002-2014.
53. Boileau C, Martel-Pelletier M, Moldovan F, Jouzeau JY, Netter P,
Manning PT, Pelletier JP: The in situ up-regulation of chondro-
cyte interleukin-1-converting enzyme and interleukin-18 levels
in experimental osteoarthritis is mediated by nitric oxide.
Arthritis Rheum 2002, 46:2637-2647.
54. Murrel GA, Jang D, Williams RJ: Nitric oxide activates metallo-
protease enzymes in articular cartilage. Biochem Biophys Res
Commun 1995, 206:15-21.
55. Järvinen TAH, Moilanen T, Järvinen TLN, Moilanen E: Nitric oxide
mediates interleukin-1 induced inhibition of glycosaminogly-
can synthesis in rat articular cartilage. Mediators Inflamm 1995,
4:107-111.
56. Taskiran D, Stefanovic-Racic M, Georgescu HI, Evans CH: Nitric
oxide mediates suppression of cartilage proteoglycan synthe-
sis by interleukin-1.  Biochem Biophys Res Commun 1994,
200:142-148.
57. Clancy R, Abramson SB, Kohne C, Rediske J: Nitric oxide atten-
uates cellular hexose monophosphate shunt response to oxi-
dants in articular chondrocytes and acts to promote oxidant
injury. J Cell Physiol 1997, 172:183-191.
58. Henrotin YE, Zheng SX, Deby GP, Labasse AH, Crielaard JM,
Reginster JY: Nitric oxide downregulates interleukin-1-stimu-
lated IL-6, IL-8, and prostaglandin E2 production by human
chondrocytes. J Rheumatol 1998, 25:1595-1601.Arthritis Research & Therapy    Vol 7 No 5    Ea et al.
R926
59. Cai L, Suboc S, Hogue DA, Fei DTW, Filvaroff EH: Interleukin 17
induced nitric oxide suppresses matrix synthesis and cartilage
from matrix breakdown. J Rheumatol 2002, 29:1725-1736.
60. Amin AR, Attur M, Patel RN, Thakker GD, Marshall PJ, Rediske J,
Stuchin SA, Patel IR, Abramson SB: Superinduction of cycloox-
ygenase-2 activity in human osteoarthritis-affected cartilage.
Influence of nitric oxide. J Clin Invest 1997, 99:1231-1237.
61. Bird JLE, May S, Bayliss MT: Nitric oxide inhibits aggrecan deg-
radation in explant culture of equine articular cartilage. Equine
Vet J 2000, 32:133-139.
62. Stichtenoth DO, Frölich JC: Nitric oxide in inflammatory joint
diseases. Br J Rheumatol 1998, 37:246-257.
63. Stefanovic-Racic M, Morales TI, Taskiran D, McIntyre LA, Evans
CH: The role of nitric oxide in proteoglycan turnover by bovine
articular cartilage organ cultures.  J Immunol 1996,
156:1213-1220.
64. Pelletier JP, Martel-Pelletier J, Abramson SB: Osteoarthritis, an
inflammatory disease: Potential implication for the selection of
new therapeutic targets. Arthritis Rheum 2001, 44:1237-1247.
65. Mendes AF, Caramona MM, Carvalho AP, Lopes MC: Role of
mitogen-activated protein kinases and tyrosine kinases on IL-
1-induced NF-κ B activation and iNOS expression in bovine
articular chondrocytes. Nitric Oxide 2002, 6:35-44.
66. LaPointe MC, Isenovic E: Interleukin-1β  regulation of inducible
nitric oxide synthase and cyclooxygenase-2 involves the p42/
44 and p38 MAPK signaling pathways in cardiac myocytes.
Hypertension 1999, 33:276-282.
67. Finder JD, Petrus JL, Hamilton A, Villavicencio RT, Pitt BR, Setbi
SM: Signal transduction pathways of IL-1β -mediated iNOS in
pulmonary vascular smooth muscle cells. Am J Physiol Lung
Cell Mol Physiol 2001, 281:L816-L823.
68. Guan Z, Buckman SY, Springer LD, Morrison AR: Both p38α MAPK
and JNK/SAPK pathways are important for induction of nitric
oxide synthase by interleukin-1β  in rat glomerular mesangial
cells. J Biol Chem 1999, 274:36200-36206.
69. Taylor BS, Geller DA: Molecular regulation of the human induc-
ible nitric oxide synthase (iNOS) gene.  Shock 2000,
13:413-424.
70. Marks-Konczalik J, Chu SC, Moss J: Cytokine-mediated tran-
scriptional induction of the human inducible nitric oxide syn-
thase gene requires both activator protein 1 and nuclear factor
κ B-binding sites. J Biol Chem 1998, 273:22201-22208.